EBCI partners with Nuvation Bio to educate brain cancer patients about SIGMA trial

The End Brain Cancer Initiative is partnering with Nuvation Bio to help educate patients, caregivers and clinicians about the SIGMA phase 3 study in IDH1-mutant glioma. The effort comes as Parts 2 and 3 of the trial are now enrolling for certain Grade 2, 3 and 4 brain cancers.

Why it matters: - The partnership is aimed at helping patients and caregivers understand a late-stage brain cancer trial that could expand treatment options for people with IDH1-mutant glioma. - SIGMA is studying safusidenib across multiple glioma populations, including some patients with high-risk or recurrent disease. - Patient education matters because eligibility depends on tumor type, grade, mutation status and prior treatment.

What happened: - The End Brain Cancer Initiative partnered with Nuvation Bio to provide patient disease education around the SIGMA trial. - The effort covers brain cancer patients with Grade 2, 3 or 4 glioma. - The announcement was issued in Seattle on Oct. 15, 2026.

The details: - SIGMA is a phase 3 study evaluating investigational safusidenib in IDH1-mutant glioma. - Part 1 evaluated the efficacy, safety and pharmacokinetic characteristics of safusidenib in participants with recurrent or progressive IDH1-mutant WHO Grade 2 or Grade 3 glioma. - Part 1 is no longer enrolling. - Part 2 is evaluating maintenance safusidenib versus placebo in IDH1-mutant Grade 2 or Grade 3 astrocytoma with high-risk features or IDH1-mutant Grade 4 astrocytoma. - Part 2 follows standard-of-care radiation or chemoradiation and adjuvant temozolomide. - Part 2 is randomized, double-blind and placebo-controlled. - Part 2 is now enrolling. - Part 3 is evaluating safusidenib in participants with residual or recurrent IDH1-mutant Grade 3 oligodendroglioma who have received surgery as their only treatment. - Part 3 is an open-label, single-arm cohort. - Part 3 is now enrolling. - Patients, caregivers and healthcare providers can learn more at more information. - Nuvation Bio describes safusidenib as a brain-penetrant IDH1 inhibitor. - Nuvation Bio's pipeline also includes taletrectinib, an innovative drug-drug conjugate program, and IBTROZI, a next-generation ROS1 inhibitor. - Nuvation Bio was founded in 2018 by biopharma veteran David Hung, who previously founded Medivation, Inc. - Nuvation Bio has offices in New York, San Francisco, Boston and Shanghai.

Between the lines: - The partnership extends trial awareness beyond a sponsor announcement and into patient outreach, which can matter in rare or complex cancers where eligibility is narrow and trial access is uneven. - The focus on education suggests both organizations want more informed referrals from patients, caregivers and clinicians, not just general awareness. - The correction in the headline underscores that the trial details and study phases matter, especially when publicizing enrollment status.

What's next: - Enrollment continues for Part 2 and Part 3 of SIGMA. - Patients and providers seeking details are being directed to the EBCI landing page. - Nuvation Bio and EBCI are likely to continue using the partnership to drive awareness of trial participation opportunities for eligible glioma patients.

The bottom line: - EBCI and Nuvation Bio are using patient education to help connect eligible glioma patients with an enrolling phase 3 study of safusidenib.